Evidence map›Paper›PMID 17259486›Full record

ArticleDiabetes care2007

Progression from newly acquired impaired fasting glusose to type 2 diabetes.

Gregory A Nichols, Teresa A Hillier, Jonathan B Brown

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 107 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03141398 withdrawnnot on this mapstarted 2017, after this paper: background citation

Continuous Glucose Monitoring (CGM) Versus Oral Glucose Tolerance Test (OGTT) Versus T2* MRI Of The Pancreas In High-Risk Group (Hemoglobinopathies, Lymphoma & Acute Lymphoblastic Leukemia): A Comparative Study

TypeobservationalSponsorHamad Medical CorporationRan2017 to 2018Enrolled0ConditionsIron Overload, Hemoglobinopathies, Lymphoma, Acute Lymphoblastic LeukemiaArmsContinuous Glucose Monitoring (CGM), Oral Glucose Tolerance Test (OGTT), T2* MRI of the Pancreas
NCT03617757 nacompletednot on this mapstarted 2017, after this paper: background citation

Determinants of Progression From Impaired Fasting Glucose to Diabetes Mellitus Among Chinese - a 3-year Follow up Study

TypeinterventionalSponsorThe University of Hong KongRan2017 to 2019Enrolled386ConditionsProgression From Impaired Fasting Glucose to Diabetes MellitusArmsOral Glucose Tolerance Test, HbA1c
3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gregory A NicholsCenter for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227-1098, USA. greg.nichols@kpchr.org
Teresa A Hillier
Jonathan B Brown
Kaiser Permanente Center for Health Research · US

Funding

Characteristics and Costs of Impaired Fasting GlucoseR21DK063961 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI NICHOLS, GREGORY A · 2004 to 2005
$316k
NIDDK NIH HHS R21 DK063961NIDDK NIH HHS R21 DK 063961-02
6 · The paper itself

Abstract

objectiveWe sought to estimate the rate of progression from newly acquired (incident) impaired fasting glucose (IFG) to diabetes under the old and new IFG criteria and to identify predictors of progression to diabetes. RESEARCH DESIGN AND

methodsWe identified 5,452 members of an HMO with no prior history of diabetes, with at least two elevated fasting glucose tests (100-125 mg/dl) measured between 1 January 1994 and 31 December 2003, and with a normal fasting glucose test before the two elevated tests. All data were obtained from electronic records of routine clinical care. Subjects were followed until they developed diabetes, died, left the health plan, or until 31 December 2005.

resultsOverall, 8.1% of subjects whose initial abnormal fasting glucose was 100-109 mg/dl (added IFG subjects) and 24.3% of subjects whose initial abnormal fasting glucose was 110-125 mg/dl (original IFG subjects) developed diabetes (P < 0.0001). Added IFG subjects who progressed to diabetes did so within a mean of 41.4 months, a rate of 1.34% per year. Original IFG subjects converted at a rate of 5.56% per year after an average of 29.0 months. A steeper rate of increasing fasting glucose; higher BMI, blood pressure, and triglycerides; and lower HDL cholesterol predicted diabetes development.

conclusionsTo our knowledge, these are the first estimates of diabetes incidence from a clinical care setting when the date of IFG onset is approximately known under the new criterion for IFG. The older criterion was more predictive of diabetes development. Many newly identified IFG patients progress to diabetes in <3 years, which is the currently recommended screening interval.

Indexed as

Disease ProgressionAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2FastingFemaleFollow-Up StudiesGlucose IntoleranceHealth Maintenance OrganizationsHumansMaleMiddle AgedOregonRetrospective StudiesTime FactorsBlood Glucose

Identifiers

PMID17259486
PMCPMC1851903
OpenAlexW2153509994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.